Celldex Therapeutics Inc. (CLDX)

3.18
NASDAQ : Health Technology
Prev Close 3.11
Day Low/High 3.11 / 3.23
52 Wk Low/High 2.75 / 11.62
Avg Volume 434.90K
Exchange NASDAQ
Shares Outstanding 13.77M
Market Cap 42.82M
EPS -14.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

No Reason to Jump Long

No Reason to Jump Long

I'm content to sit in cash and wait for a trigger.

A Brick Wall for Bulls

A Brick Wall for Bulls

The S&P is putting up strong resistance that has withstood several attacks today.

'Mad Money' Lightning Round: I Want You to Buy Costco

'Mad Money' Lightning Round: I Want You to Buy Costco

Cramer loves Six Flags and prefers IBM to AutoDesk.

Jim Cramer's 'Mad Money' Recap: Hope Springs Eternal

Jim Cramer's 'Mad Money' Recap: Hope Springs Eternal

Investors are hopeful the economy is really improving, and that's why some stocks are surging again, Cramer says.

Fitz Bits: Careful With Those Highfliers

Fitz Bits: Careful With Those Highfliers

In other words, don't overstay your welcome.

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio received good news from Germany in February but didn't tell investors until Monday.

Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)

Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due

Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due

Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?

Celldex Reports Fiscal 2013 Business/Financial Results And Outlines 2014 Strategy

Celldex Reports Fiscal 2013 Business/Financial Results And Outlines 2014 Strategy

- Management to Host Conference Call Today, Monday, March 3, at 8:30 a.m. Eastern Time -

Celldex To Report Fourth Quarter And Fiscal 2013 Business/Financial Results And Host 2014 Strategy Conference Call

Celldex To Report Fourth Quarter And Fiscal 2013 Business/Financial Results And Host 2014 Strategy Conference Call

Conference Call Scheduled for Monday, March 3, at 8:30 a.m. Eastern Time

Celldex Therapeutics Inc. (CLDX): Today's Featured Health Care Laggard

Celldex Therapeutics Inc. (CLDX): Today's Featured Health Care Laggard

Celldex Therapeutics was a leading decliner within the health care sector, falling $0.55 (-2.0%) to $27.45 on light volume

Use Options For a Chance To Buy CLDX at a 62% Discount

Use Options For a Chance To Buy CLDX at a 62% Discount

Looking back to 71 days ago, Celldex Therapeutics priced a 7,000,000 share secondary stock offering at $24.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Thursday, the stock is now 10% above the offering price.

First Week of March 22nd Options Trading For Celldex Therapeutics (CLDX)

First Week of March 22nd Options Trading For Celldex Therapeutics (CLDX)

Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the March 22nd expiration.

Use Options For a Chance To Buy CLDX at a 58% Discount

Use Options For a Chance To Buy CLDX at a 58% Discount

Looking back to 42 days ago, Celldex Therapeutics priced a 7,000,000 share secondary stock offering at $24.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday, the stock is now 10.3% higher than the offering price.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.

Good Luck Chasing Celldex

Good Luck Chasing Celldex

Right now, investors who buy at this level will be on the wrong side of the trade.

Celldex Therapeutics (CLDX) Is Today's Perilous Reversal Stock

Celldex Therapeutics (CLDX) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Announces Exercise Of Underwriters' Option To Purchase Additional Shares

Celldex Announces Exercise Of Underwriters' Option To Purchase Additional Shares

Celldex proceeds from offering total $191.4 million gross; $181.9 million net

Celldex Therapeutics (CLDX) Moving On Heavy Pre-Market Trading

Celldex Therapeutics (CLDX) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a pre-market mover with heavy volume candidate

Today's Post-Market Laggard Is Celldex Therapeutics (CLDX)

Today's Post-Market Laggard Is Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a post-market laggard candidate

Celldex Therapeutics Initiates METRIC, An Accelerated Approval Study Of Glembatumumab Vedotin In Patients With Triple Negative Breast Cancer

Celldex Therapeutics Initiates METRIC, An Accelerated Approval Study Of Glembatumumab Vedotin In Patients With Triple Negative Breast Cancer

Antibody drug conjugate targets gpNMB, a protein which promotes the migration, invasion and metastasis of breast cancer

TheStreet Quant Rating: D- (Sell)